Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Wolfgang Miesbach on AAV5 Antibodies in Hemophilia B Gene Therapy
Wolfgang Miesbach, Robert Klamroth, Sandra Le Quellec/LinkedIn
Aug 25, 2025, 08:16

Wolfgang Miesbach on AAV5 Antibodies in Hemophilia B Gene Therapy

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:

“New study on AAV5 antibodies in haemophilia B gene therapy. We just published in Molecular Therapy – Methods and Clinical Development on how AAV5 antibodies behave over time in adults with haemophilia B.

This analysis is based on the HOPE-B phase 3 trial with 67 patients in the US and Europe.

Importantly, for etranocogene dezaparvovec, AAV5 NAb positivity is not a strict contraindication. But very high titers may reduce transduction efficiency. That’s why NAb screening is an essential part of assessing eligibility for commercial gene therapy.

Key findings:

  • 48% of patients had neutralizing antibodies (NAbs) at screening (median titer 58; range 9–3440)
  • Levels remained stable over 8 months ( median variation 25%; range 2–154%)
  • Strong correlation between NAbs and IgG (r=0.96)
  • Fewer than 5% switched from negative to positive
  • ~10% seroreverted from positive to negative
  • NAb positivity was more frequent in patients ≥50 years (p=0.0065)

Why this matters?
NAb test results were consistent over months. Screening can be done up to 8 months before gene therapy infusion, giving more flexibility for clinical planning.

Thanks to Robert Klamroth and Sandra Le Quellec for leading this work, and to CSL for supporting the study.”

Read the full article here.

Article: Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study

Authors: Robert Klamroth, Michael Recht, Nigel S. Key, Wolfgang Miesbach, Steven W. Pipe, Radoslaw Kaczmarek, Douglass Drelich, Blanca Salazar, Sandra Le Quellec, Paul E. Monahan, Nicholas Galante, Paul van der Valk, Jacqueline Tarrant

Wolfgang Miesbach on AAV5 Antibodies in Hemophilia B Gene Therapy

Stay updated on all scientific advances in the field of Hemophilia with Hemostasis Today.

AAV5 inhibitors Blanca Salazar bleeding disorders Douglass Drelich Gene therapy Health Hematology Hemophilia B Hemostasis Today HOPE B Jacqueline Tarrant Medicine Michael Recht Nicholas Galante Nigel S. Key Paul E. Monahan Paul van der Valk Radoslaw Kaczmarek Robert Klamroth Sandra Le Quellec Steven W. Pipe Wolfgang Miesbach
NewsFeed